Search

Your search keyword '"Manga, S."' showing total 146 results
Start Over Author "Manga, S."

Refine your results

more »

more »

more »

more »
146 results on '"Manga, S."'

2. Assessment of the Phytoremediation Activity of the Rhizobacterial Flora of Arachis hypogaea (Groundnut) on Hydrocarbon Contaminated Soil

Author

Manga, S. S., Nwosu, C. O., Bazata, Y. A., and Isah, M.

Subjects
Arachis hypogaea, Bacteria flora, Hydrocarbon-Contaminated Soil, Oil Spillage, Phytoremediation, Microbiology, QR1-502
Abstract

Over the years, Nigeria’s development has accelerated due to crude oil exploaration. In spite of its enormous benefits, it has wreaked much havoc and damage on the ecosystem due to its toxicity. The study evaluated hydrocarbon degradation potentials by the rhizobacterial flora of the legume Arachis hypogaea (Groundnut) grown in potted sandy-loamy soil samples in the green house of Kebbi State University of Science and Technology, Aliero, Nigeria. Crude oil concentrations of 0.5, 1.0, 2.0, 2.5, 5.0, 10.0, 15.0, and 20.0mls were used to contaminate the soil samples respectively. All soil samples apart from the control were polluted. Groundnut germinated after seven days at concentration of 0.0 to 2.5% but at higher concentration of 5.0% of the contaminant, the germination time increased to nine days and at concentration 20%, it increased to ten (10) days. Even though groundnut germination was observed in all concentrations of crude oil tested, significant shoot retardation still occurs in both legumes consequent on crude oil toxicity. Rhizobacterial population also diminished with increase in crude oil concentration. The rhizobacterial population diminished with increase in crude oil concentration. The rhizobacteria isolated from the soil sample include Bacillus subtilis, Clostridium tetani, Staphylococcus aureus, Proteus vulgaris, and Enterobacter aerogenes. Rhizobacterial population also diminished with increase in crude oil concentration. The study revealed the resistance of groundnut to crude oil (p

Published
2019
Full Text
View/download PDF

3. Clinical standards for the assessment, management and rehabilitation of post-TB lung disease

Author

Migliori, GB, Marx, FM, Ambrosino, N, Zampogna, E, Schaaf, HS, van der Zalm, MM, Allwood, B, Byrne, AL, Mortimer, K, Wallis, RS, Fox, GJ, Leung, CC, Chakaya, JM, Seaworth, B, Rachow, A, Marais, BJ, Furin, J, Akkerman, OW, Al Yaquobi, F, Amaral, AFS, Borisov, S, Caminero, JA, Carvalho, ACC, Chesov, D, Codecasa, LR, Teixeira, RC, Dalcolmo, MP, Datta, S, Dinh-Xuan, A-T, Duarte, R, Evans, CA, García-García, J-M, Günther, G, Hoddinott, G, Huddart, S, Ivanova, O, Laniado-Laborín, R, Manga, S, Manika, K, Mariandyshev, A, Mello, FCQ, Mpagama, SG, Muñoz-Torrico, M, Nahid, P, Ong, CWM, Palmero, DJ, Piubello, A, Pontali, E, Silva, DR, Singla, R, Spanevello, A, Tiberi, S, Udwadia, ZF, Vitacca, M, Centis, R, D Ambrosio, L, Sotgiu, G, Lange, C, and Visca, D

Subjects
Lung, Clinical Research, 7.3 Management and decision making, Management of diseases and conditions, Good Health and Well Being, Humans, Consensus, Lung Diseases, Quality of Life, Tuberculosis, tuberculosis, post-TB lung disease, se-quelae, pulmonary rehabilitation, clinical standards, Cardiorespiratory Medicine and Haematology, Microbiology
Abstract

BACKGROUND: Increasing evidence suggests that post-TB lung disease (PTLD) causes significant morbidity and mortality. The aim of these clinical standards is to provide guidance on the assessment and management of PTLD and the implementation of pulmonary rehabilitation (PR).METHODS: A panel of global experts in the field of TB care and PR was identified; 62 participated in a Delphi process. A 5-point Likert scale was used to score the initial ideas for standards and after several rounds of revision the document was approved (with 100% agreement).RESULTS: Five clinical standards were defined: Standard 1, to assess patients at the end of TB treatment for PTLD (with adaptation for children and specific settings/situations); Standard 2, to identify patients with PTLD for PR; Standard 3, tailoring the PR programme to patient needs and the local setting; Standard 4, to evaluate the effectiveness of PR; and Standard 5, to conduct education and counselling. Standard 6 addresses public health aspects of PTLD and outcomes due to PR.CONCLUSION: This is the first consensus-based set of Clinical Standards for PTLD. Our aim is to improve patient care and quality of life by guiding clinicians, programme managers and public health officers in planning and implementing adequate measures to assess and manage PTLD.

Published
2021

4. Optimal Control Analysis of Isolation and Treatment Strategies on the Transmission Dynamics and Control of Lassa Fever.

Author

Anka, G. H., Abdulrahman, S., Haliru, A. A., Manga, S. S., and Abubakar, S. F.

Subjects
LASSA fever, OPTIMAL control theory, RODENT populations, PONTRYAGIN'S minimum principle, POPULATION
Abstract

This study constructed and examined a mathematical model on the dynamics of Lassa fever transmission and control. We took into account two interacting rodent and human populations. There are six groups within the human population, one of which is made up of people who underwent complicated recovery. Additionally, there are three divisions within the rodent population. The reduction of susceptible, latent, and infectious individuals by treatment and isolation is the main goal of this work. The goal of optimality is to reduce the number of latent and infectious individuals through isolation and treatment. The amount of influence of the controls in lowering the population of causal pathogens and susceptible, latent, and infectious people is determined by applying the optimal control theory. The model's optimal solution was established using Pontryagin's maximum principle, and the optimal system was then generated and solved numerically. Graphs were used to create simulations showing how the controls affected susceptible, latent, and infected persons. The results demonstrated that applying the two controls simultaneously can be one of the quick and efficient strategies to regulate Lassa Fever. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort

Author

Koirala, S., Borisov, S., Danila, E., Mariandyshev, A., Shrestha, B., Lukhele, N., Dalcolmo, M., Shakya, S.R., Miliauskas, S., Kuksa, L., Manga, S., Aleksa, A., Denholm, J.T., Khadka, H.B., Skrahina, A., Diktanas, S., Ferrarese, M., Bruchfeld, J., Koleva, A., Piubello, A., Koirala, G.S., Udwadia, Z.F., Palmero, D.J., Munoz-Torrico, M., GC, R., Gualano, G., Grecu, V.I., Motta, I., Papavasileiou, A., Li, Y., Hoefsloot, W., Kunst, H., Mazza-Stalder, J., Payen, M.-C., Akkerman, O.W., Bernal, E., Manfrin, V., Matteelli, A., Mustafa Hamdan, H., Nieto Marcos, M., Cadiñanos Loidi, J., Cebrian Gallardo, J.J., Duarte, R., Escobar Salinas, N., Gomez Rosso, R., Laniado-Laborín, R., Martínez Robles, E., Quirós Fernandez, S., Rendon, A., Solovic, I., Tadolini, M., Viggiani, P., Belilovski, E., Boeree, M.J., Cai, Q., Davidavičienė, E., Forsman, L.D., De Los Rios, J., Drakšienė, J., Duga, A., Elamin, S.E., Filippov, A., Garcia, A., Gaudiesiute, I., Gavazova, B., Gayoso, R., Gruslys, V., Jonsson, J., Khimova, E., Madonsela, G., Magis-Escurra, C., Marchese, V., Matei, M., Moschos, C., Nakčerienė, B., Nicod, L., Palmieri, F., Pontarelli, A., Šmite, A., Souleymane, M.B., Vescovo, M., Zablockis, R., Zhurkin, D., Alffenaar, J.-W., Caminero, J.A., Codecasa, L.R., García-García, J.-M., Esposito, S., Saderi, L., Spanevello, A., Visca, D., Tiberi, S., Pontali, E., Centis, R., D'Ambrosio, L., van den Boom, M., Sotgiu, G., and Migliori, G.B.

Published
2021
Full Text
View/download PDF

6. MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network

Author

Arkub, T. Abu, Akkerman, O.W., Aleksa, A., Belilovski, E., Bernal, E., Blanc, F-X., Boeree, M., Borisov, S., Bruchfeld, J., Cadiñanos Loidi, J., Caminero, J.A., Carvalho, A.C., Cebrian Gallardo, J.J., Charalampos, Danila, E., Davies Forsman, L., Denholm, J., Dheda, K., Diel, R., Diktanas, S., Dobler, C., Enwerem, M., Esposito, S., Escobar Salinas, N., Filippov, A., Formenti, B., García García, J.M., Goletti, D., Gomez Rosso, R., Gualano, G., Isaakidis, P., Kaluzhenina, A., Koirala, S., Kuksa, L., Kunst, H., Li, Y., Magis-Escurra, C., Manfrin, V., Manga, S., Manika, K., Marchese, V., Martínez Robles, E., Maryandyshev, A., Matteelli, A., Mariani, A., Mazza-Stalder, J., Mello, F., Mendoza, L., Mesi, A., Miliauskas, S., Mustafa Hamdan, H., Ndjeka, N., Nieto Marcos, M., Ottenhoff, T.H.M., Palmero, D.J., Palmieri, F., Papavasileiou, A., Payen, M.C., Pontarelli, A., Pretti Dalcolmo, M., Quirós Fernandez, S., Romero, R., Rossato Silva, D., Santos, A.P., Seaworth, B., Sinitsyn, M., Skrahina, A., Solovic, I., Spanevello, A., Tadolini, M., Torres, C., Udwadia, Z., van den Boom, M., Volchenkov, G.V., Yedilbayev, A., Zaleskis, R., Zellweger, J.P., Migliori, Giovanni Battista, Tiberi, Simon, Zumla, Alimuddin, Petersen, Eskild, Chakaya, Jeremiah Muhwa, Wejse, Christian, Muñoz Torrico, Marcela, Duarte, Raquel, Alffenaar, Jan Willem, Schaaf, H. Simon, Marais, Ben J., Cirillo, Daniela Maria, Alagna, Riccardo, Rendon, Adrian, Pontali, Emanuele, Piubello, Alberto, Figueroa, José, Ferlazzo, Gabriella, García-Basteiro, Alberto, Centis, Rosella, Visca, Dina, D’Ambrosio, Lia, and Sotgiu, Giovanni

Published
2020
Full Text
View/download PDF

7. Barriers and facilitators of follow-up among women with precancerous lesions of the cervix in Cameroon: a qualitative pilot study

Author

Manga S, Kiyang E, and DeMarco RF

Subjects
Cervical precancer, Follow-up, HIV infected women, and HIV uninfected women, Gynecology and obstetrics, RG1-991
Abstract

Simon Manga,1,2 Edith Kiyang,1 Rosanna F DeMarco2 1Women’s Health Program, Cameroon Baptist Convention Health Services, Bamenda, Cameroon; 2College of Nursing and Health Sciences, University of Massachusetts Boston, Boston, MA, USA Purpose: This pilot study explores the barriers to adherence to follow-up among women with cervical precancer in urban Cameroon. While follow-up of women with a positive screening of cervical precancer is the most important aspect of cervical cancer secondary prevention, women with cervical precancer do not adhere frequently to recommended follow-up schedule in Cameroon. The aim of the study was to explore and describe the barriers and facilitators to follow-up for cervical precancer among women infected and uninfected with HIV in Cameroon. Participants and methods: A qualitative research design was used to answer the research questions. Participants included eight HIV-infected and -uninfected women diagnosed with cervical precancer and 19 nurses. Data were collected by in-depth individual patient interviews and focus groups with nurses. An interview guide with open-ended questions, using the social ecological model as a framework, included questions that addressed the complexities of the lives of individuals and professionals within a relational context. The interviews were audio-taped and transcribed verbatim in English language. Thematic analysis of data was completed with no epistemological or theoretical perspective underpinning the analyses. Results: Four major themes emerged from the study. They were clinic, personal, and social barriers, and strategies to improve follow-up. Conclusion: The use of reminder phone calls and fee reduction, coupled with peer counseling and navigation of women who have been diagnosed with cervical precancer, could be effective ways of improving adherence to follow-up. Further research is needed to explore the same phenomenon among women in rural areas, especially those who were initially attended to in mobile clinics. Keywords: cervical precancer, follow-up, HIV-infected women, HIV-uninfected women

Published
2019

8. Clinical standards for the management of adverse effects during treatment for TB

Author

Singh, K. P., primary, Carvalho, A. C. C., additional, Centis, R., additional, D´Ambrosio, L., additional, Migliori, G. B., additional, Mpagama, S. G., additional, Nguyen, B. C., additional, Aarnoutse, R. E., additional, Aleksa, A., additional, van Altena, R., additional, Bhavani, P. K., additional, Bolhuis, M. S., additional, Borisov, S., additional, van´t Boveneind-Vrubleuskaya, N., additional, Bruchfeld, J., additional, Caminero, J. A., additional, Carvalho, I., additional, Cho, J. G., additional, Davies Forsman, L., additional, Dedicoat, M., additional, Dheda, K., additional, Dooley, K., additional, Furin, J., additional, García-García, J. M., additional, Garcia-Prats, A., additional, Hesseling, A. C., additional, Heysell, S. K., additional, Hu, Y., additional, Kim, H. Y., additional, Manga, S., additional, Marais, B. J., additional, Margineanu, I., additional, Märtson, A-G., additional, Munoz Torrico, M., additional, Nataprawira, H. M., additional, Nunes, E., additional, Ong, C. W. M., additional, Otto-Knapp, R., additional, Palmero, D. J., additional, Peloquin, C. A., additional, Rendon, A., additional, Rossato Silva, D., additional, Ruslami, R., additional, Saktiawati, A. M. I., additional, Santoso, P., additional, Schaaf, H. S., additional, Seaworth, B., additional, Simonsson, U. S. H., additional, Singla, R., additional, Skrahina, A., additional, Solovic, I., additional, Srivastava, S., additional, Stocker, S. L., additional, Sturkenboom, M. G. G., additional, Svensson, E. M., additional, Tadolini, M., additional, Thomas, T. A., additional, Tiberi, S., additional, Trubiano, J., additional, Udwadia, Z. F., additional, Verhage, A. R., additional, Vu, D. H., additional, Akkerman, O. W., additional, Alffenaar, J. W. C., additional, and Denholm, J. T., additional

Published
2023
Full Text
View/download PDF

9. Clinical standards for the management of adverse effects during treatment for TB.

Author

Singh, K.P., Carvalho, A.C.C., Centis, R., Ambrosio, L.D., Migliori, G.B., Mpagama, S.G., Nguyen, B.C., Aarnoutse, R.E., Aleksa, A., Altena, R. van, Bhavani, P.K., Bolhuis, M.S., Borisov, S., Boveneind-Vrubleuskaya, N. Van't, Bruchfeld, J., Caminero, J.A., Carvalho, I., Cho, J.G., Davies Forsman, L., Dedicoat, M., Dheda, K., Dooley, K., Furin, J., García-García, J.M., Garcia-Prats, A., Hesseling, A.C., Heysell, S.K., Hu, Y., Kim, H.Y., Manga, S., Marais, B.J., Margineanu, I., Märtson, A.G., Munoz Torrico, M., Nataprawira, H.M., Nunes, E., Ong, C.W.M., Otto-Knapp, R., Palmero, D.J., Peloquin, C.A., Rendon, A., Rossato Silva, D., Ruslami, R., Saktiawati, A.M.I., Santoso, P., Schaaf, H.S., Seaworth, B., Simonsson, U.S.H., Singla, R., Skrahina, A., Solovic, I., Srivastava, S., Stocker, S.L., Sturkenboom, M.G.G., Svensson, E.M., Tadolini, M., Thomas, T.A., Tiberi, S., Trubiano, J., Udwadia, Z.F., Verhage, A.R., Vu, D.H., Akkerman, O.W., Alffenaar, J.W.C., Denholm, J.T., Singh, K.P., Carvalho, A.C.C., Centis, R., Ambrosio, L.D., Migliori, G.B., Mpagama, S.G., Nguyen, B.C., Aarnoutse, R.E., Aleksa, A., Altena, R. van, Bhavani, P.K., Bolhuis, M.S., Borisov, S., Boveneind-Vrubleuskaya, N. Van't, Bruchfeld, J., Caminero, J.A., Carvalho, I., Cho, J.G., Davies Forsman, L., Dedicoat, M., Dheda, K., Dooley, K., Furin, J., García-García, J.M., Garcia-Prats, A., Hesseling, A.C., Heysell, S.K., Hu, Y., Kim, H.Y., Manga, S., Marais, B.J., Margineanu, I., Märtson, A.G., Munoz Torrico, M., Nataprawira, H.M., Nunes, E., Ong, C.W.M., Otto-Knapp, R., Palmero, D.J., Peloquin, C.A., Rendon, A., Rossato Silva, D., Ruslami, R., Saktiawati, A.M.I., Santoso, P., Schaaf, H.S., Seaworth, B., Simonsson, U.S.H., Singla, R., Skrahina, A., Solovic, I., Srivastava, S., Stocker, S.L., Sturkenboom, M.G.G., Svensson, E.M., Tadolini, M., Thomas, T.A., Tiberi, S., Trubiano, J., Udwadia, Z.F., Verhage, A.R., Vu, D.H., Akkerman, O.W., Alffenaar, J.W.C., and Denholm, J.T.

Abstract

Item does not contain fulltext, BACKGROUND: Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise for the diagnosis and management of AE.METHODS: 65/81 invited experts participated in a Delphi process using a 5-point Likert scale to score draft standards.RESULTS: We identified eight clinical standards. Each person commencing treatment for TB should: Standard 1, be counselled regarding AE before and during treatment; Standard 2, be evaluated for factors that might increase AE risk with regular review to actively identify and manage these; Standard 3, when AE occur, carefully assessed and possible allergic or hypersensitivity reactions considered; Standard 4, receive appropriate care to minimise morbidity and mortality associated with AE; Standard 5, be restarted on TB drugs after a serious AE according to a standardised protocol that includes active drug safety monitoring. In addition: Standard 6, healthcare workers should be trained on AE including how to counsel people undertaking TB treatment, as well as active AE monitoring and management; Standard 7, there should be active AE monitoring and reporting for all new TB drugs and regimens; and Standard 8, knowledge gaps identified from active AE monitoring should be systematically addressed through clinical research.CONCLUSION: These standards provide a person-centred, consensus-based approach to minimise the impact of AE during TB treatment.

Published
2023

10. Clinical standards for the management of adverse effects during treatment for TB

Author

Singh, K. P., Carvalho, A. C. C., Centis, R., D'Ambrosio, L., Migliori, G. B., Mpagama, S. G., Nguyen, B. C., Aarnoutse, R. E., Aleksa, A., van Altena, R., Bhavani, P. K., Bolhuis, M. S., Borisov, S., van't Boveneind-Vrubleuskaya, N., Bruchfeld, J., Caminero, J. A., Carvalho, I., Cho, J. G., Forsman, L. Davies, Dedicoat, M., Dheda, K., Dooley, K., Furin, J., Garcia-Garcia, J. M., Garcia-Prats, A., Hesseling, A. C., Heysell, S. K., Hu, Y., Kim, H. Y., Manga, S., Marais, B. J., Margineanu, I., Martson, A-G, Torrico, M. Munoz, Nataprawira, H. M., Nunes, E., Ong, C. W. M., Otto-Knapp, R., Palmero, D. J., Peloquin, C. A., Rendon, A., Silva, D. Rossato, Ruslami, R., Saktiawati, A. M. I., Santoso, P., Schaaf, H. S., Seaworth, B., Simonsson, Ulrika S. H., Singla, R., Skrahina, A., Solovic, I., Srivastava, S., Stocker, S. L., Stukenboom, M. G. G., Svensson, Elin, Tadolini, M., Thomas, T. A., Tiberi, S., Trubiano, J., Udwadia, Z. F., Verhage, A. R., Vu, D. H., Akkerman, O. W., Alffenaar, J. W. C., Denholm, J. T., Singh, K. P., Carvalho, A. C. C., Centis, R., D'Ambrosio, L., Migliori, G. B., Mpagama, S. G., Nguyen, B. C., Aarnoutse, R. E., Aleksa, A., van Altena, R., Bhavani, P. K., Bolhuis, M. S., Borisov, S., van't Boveneind-Vrubleuskaya, N., Bruchfeld, J., Caminero, J. A., Carvalho, I., Cho, J. G., Forsman, L. Davies, Dedicoat, M., Dheda, K., Dooley, K., Furin, J., Garcia-Garcia, J. M., Garcia-Prats, A., Hesseling, A. C., Heysell, S. K., Hu, Y., Kim, H. Y., Manga, S., Marais, B. J., Margineanu, I., Martson, A-G, Torrico, M. Munoz, Nataprawira, H. M., Nunes, E., Ong, C. W. M., Otto-Knapp, R., Palmero, D. J., Peloquin, C. A., Rendon, A., Silva, D. Rossato, Ruslami, R., Saktiawati, A. M. I., Santoso, P., Schaaf, H. S., Seaworth, B., Simonsson, Ulrika S. H., Singla, R., Skrahina, A., Solovic, I., Srivastava, S., Stocker, S. L., Stukenboom, M. G. G., Svensson, Elin, Tadolini, M., Thomas, T. A., Tiberi, S., Trubiano, J., Udwadia, Z. F., Verhage, A. R., Vu, D. H., Akkerman, O. W., Alffenaar, J. W. C., and Denholm, J. T.

Abstract

BACKGROUND: Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise for the diagnosis and management of AE. METHODS: 65/81 invited experts participated in a Delphi process using a 5-point Likert scale to score draft standards. RESULTS: We identified eight clinical standards. Each person commencing treatment for TB should: Standard 1, be counselled regarding AE before and during treatment; Standard 2, be evaluated for factors that might increase AE risk with regular review to actively identify and manage these; Standard 3, when AE occur, carefully assessed and possible allergic or hypersensitiv-ity reactions considered; Standard 4, receive appropriate care to minimise morbidity and mortality associated with AE; Standard 5, be restarted on TB drugs after a serious AE according to a standardised protocol that includes active drug safety monitoring. In addition: Standard 6, healthcare workers should be trained on AE including how to counsel people undertaking TB treatment, as well as active AE monitoring and management; Standard 7, there should be active AE monitoring and reporting for all new TB drugs and regimens; and Standard 8, knowledge gaps identified from active AE monitoring should be systematically addressed through clinical research. CONCLUSION: These standards provide a person -centred, consensus-based approach to minimise the impact of AE TB treatment.

Published
2023
Full Text
View/download PDF

13. Tuberculosis and COVID-19 co-infection: description of the global cohort

Author

Casco, N, Jorge, AL, Palmero, DJ, Alffenaar, J-W, Denholm, J, Fox, GJ, Ezz, W, Cho, J-G, Skrahina, A, Solodovnikova, V, Bachez, P, Piubello, A, Arbex, MA, Alves, T, Rabahi, MF, Pereira, GR, Sales, R, Silva, DR, Saffie, MM, Miranda, RC, Cancino, V, Carbonell, M, Cisterna, C, Concha, C, Cruz, A, Salinas, NE, Revillot, ME, Valdes, JF, Fernandez, I, Flores, X, Tapia, PG, Garavagno, A, Vera, CG, Bahamondes, MH, Merino, LM, Munoz, E, Munoz, C, Navarro, I, Subiabre, JN, Ortega, C, Palma, S, Pradenas, AM, Pereira, G, Castillo, PP, Pinto, M, Pizarro, R, Bidegain, FR, Rodriguez, P, Sanchez, C, Salinas, AS, Soto, A, Taiba, C, Venegas, M, Riquelme, MSV, Vilca, E, Villalon, C, Yucra, E, Li, Y, Guelvez, B, Plaza, RV, Hoyos, KYT, Andrejak, C, Blanc, F-X, Dourmane, S, Froissart, A, Izadifar, A, Riviere, F, Schlemmer, F, Manika, K, Diallo, BD, Hassane-Harouna, S, Artiles, N, Mejia, LA, Gupta, N, Ish, P, Mishra, G, Sharma, S, Singla, R, Udwadia, ZF, Alladio, F, Angeli, F, Calcagno, A, Centis, R, Codecasa, LR, D'Ambrosio, L, Lauretis, AD, Esposito, S, Formenti, B, Gaviraghi, A, Giacomet, V, Goletti, D, Gualano, G, Matteelli, A, Migliori, GB, Motta, I, Palmieri, F, Pontali, E, Prestileo, T, Riccardi, N, Saderi, L, Saporiti, M, Sotgiu, G, Stochino, C, Tadolini, M, Torre, A, Villa, S, Visca, D, Danila, E, Diktanas, S, Ridaura, RL, Lopez, FLL, Torrico, MM, Rendon, A, Akkerman, OW, Souleymane, MB, Al-Abri, S, Alyaquobi, F, Althohli, K, Aizpurua, E, Gonzales, R, Jurado, J, Loban, A, Aguirre, S, Teixeira, RC, De Egea, V, Irala, S, Medina, A, Sequera, G, Sosa, N, Vazquez, F, Llanos-Tejada, FK, Manga, S, Villanueva-Villegas, R, Araujo, D, Duarte, R, Marques, TS, Grecu, VI, Socaci, A, Barkanova, O, Bogorodskaya, M, Borisov, S, Mariandyshev, A, Kaluzhenina, A, Vukicevic, TA, Stosic, M, Beh, D, Ng, D, Ong, CWM, Solovic, I, Dheda, K, Gina, P, Caminero, JA, Cardoso-Landivar, J, Galvao, MLDS, Dominguez-Castellano, A, Garcia-Garcia, J-M, Pinargote, IM, Fernandez, SQ, Sanchez-Montalva, A, Huguet, ET, Murguiondo, MZ, Bart, P-A, Mazza-Stalder, J, Bakko, F, Barnacle, J, Brown, A, Chandran, S, Killington, K, Man, K, Papineni, P, Tiberi, S, Utjesanovic, N, Zenner, D, Hearn, JL, Heysell, S, Young, L, Casco, N, Jorge, AL, Palmero, DJ, Alffenaar, J-W, Denholm, J, Fox, GJ, Ezz, W, Cho, J-G, Skrahina, A, Solodovnikova, V, Bachez, P, Piubello, A, Arbex, MA, Alves, T, Rabahi, MF, Pereira, GR, Sales, R, Silva, DR, Saffie, MM, Miranda, RC, Cancino, V, Carbonell, M, Cisterna, C, Concha, C, Cruz, A, Salinas, NE, Revillot, ME, Valdes, JF, Fernandez, I, Flores, X, Tapia, PG, Garavagno, A, Vera, CG, Bahamondes, MH, Merino, LM, Munoz, E, Munoz, C, Navarro, I, Subiabre, JN, Ortega, C, Palma, S, Pradenas, AM, Pereira, G, Castillo, PP, Pinto, M, Pizarro, R, Bidegain, FR, Rodriguez, P, Sanchez, C, Salinas, AS, Soto, A, Taiba, C, Venegas, M, Riquelme, MSV, Vilca, E, Villalon, C, Yucra, E, Li, Y, Guelvez, B, Plaza, RV, Hoyos, KYT, Andrejak, C, Blanc, F-X, Dourmane, S, Froissart, A, Izadifar, A, Riviere, F, Schlemmer, F, Manika, K, Diallo, BD, Hassane-Harouna, S, Artiles, N, Mejia, LA, Gupta, N, Ish, P, Mishra, G, Sharma, S, Singla, R, Udwadia, ZF, Alladio, F, Angeli, F, Calcagno, A, Centis, R, Codecasa, LR, D'Ambrosio, L, Lauretis, AD, Esposito, S, Formenti, B, Gaviraghi, A, Giacomet, V, Goletti, D, Gualano, G, Matteelli, A, Migliori, GB, Motta, I, Palmieri, F, Pontali, E, Prestileo, T, Riccardi, N, Saderi, L, Saporiti, M, Sotgiu, G, Stochino, C, Tadolini, M, Torre, A, Villa, S, Visca, D, Danila, E, Diktanas, S, Ridaura, RL, Lopez, FLL, Torrico, MM, Rendon, A, Akkerman, OW, Souleymane, MB, Al-Abri, S, Alyaquobi, F, Althohli, K, Aizpurua, E, Gonzales, R, Jurado, J, Loban, A, Aguirre, S, Teixeira, RC, De Egea, V, Irala, S, Medina, A, Sequera, G, Sosa, N, Vazquez, F, Llanos-Tejada, FK, Manga, S, Villanueva-Villegas, R, Araujo, D, Duarte, R, Marques, TS, Grecu, VI, Socaci, A, Barkanova, O, Bogorodskaya, M, Borisov, S, Mariandyshev, A, Kaluzhenina, A, Vukicevic, TA, Stosic, M, Beh, D, Ng, D, Ong, CWM, Solovic, I, Dheda, K, Gina, P, Caminero, JA, Cardoso-Landivar, J, Galvao, MLDS, Dominguez-Castellano, A, Garcia-Garcia, J-M, Pinargote, IM, Fernandez, SQ, Sanchez-Montalva, A, Huguet, ET, Murguiondo, MZ, Bart, P-A, Mazza-Stalder, J, Bakko, F, Barnacle, J, Brown, A, Chandran, S, Killington, K, Man, K, Papineni, P, Tiberi, S, Utjesanovic, N, Zenner, D, Hearn, JL, Heysell, S, and Young, L

Abstract

BACKGROUND: Information on tuberculosis (TB) and coronavirus disease 2019 (COVID-19) is still limited. The aim of this study was to describe the features of the TB/COVID-19 co-infected individuals from a prospective, anonymised, multicountry register-based cohort with special focus on the determinants of mortality and other outcomes. METHODS: We enrolled all patients of any age with either active TB or previous TB and COVID-19. 172 centres from 34 countries provided individual data on 767 TB-COVID-19 co-infected patients, (>50% population-based). RESULTS: Of 767 patients, 553 (74.0%) out of 747 had TB before COVID-19 (including 234 out of 747 with previous TB), 71 (9.5%) out of 747 had COVID-19 first and 123 (16.5%) out of 747 had both diseases diagnosed within the same week (n=35 (4.6%) on the same day). 85 (11.08%) out of 767 patients died (41 (14.2%) out of 289 in Europe and 44 (9.2%) out of 478 outside Europe; p=0.03): 42 (49.4%) from COVID-19, 31 (36.5%) from COVID-19 and TB, one (1.2%) from TB and 11 from other causes. In the univariate analysis on mortality the following variables reached statistical significance: age, male gender, having more than one comorbidity, diabetes mellitus, cardiovascular disease, chronic respiratory disease, chronic renal disease, presence of key symptoms, invasive ventilation and hospitalisation due to COVID-19. The final multivariable logistic regression model included age, male gender and invasive ventilation as independent contributors to mortality. CONCLUSION: The data suggest that TB and COVID-19 are a "cursed duet" and need immediate attention. TB should be considered a risk factor for severe COVID disease and patients with TB should be prioritised for COVID-19 preventative efforts, including vaccination.

Published
2022

14. Clinical standards for the diagnosis, treatment and prevention of TB infection

Author

Migliori, GB, Wu, SJ, Matteelli, A, Zenner, D, Goletti, D, Ahmedov, S, Al-Abri, S, Allen, DM, Balcells, ME, Garcia-Basteiro, AL, Cambau, E, Chaisson, RE, Chee, CBE, Dalcolmo, MP, Denholm, JT, Erkens, C, Esposito, S, Farnia, P, Friedland, JS, Graham, S, Hamada, Y, Harries, AD, Kay, AW, Kritski, A, Manga, S, Marais, BJ, Menzies, D, Ng, D, Petrone, L, Rendon, A, Silva, DR, Schaaf, HS, Skrahina, A, Sotgiu, G, Thwaites, G, Tiberi, S, Tukvadze, N, Zellweger, J-P, Ambrosio, LD, Centis, R, Ong, CWM, Migliori, GB, Wu, SJ, Matteelli, A, Zenner, D, Goletti, D, Ahmedov, S, Al-Abri, S, Allen, DM, Balcells, ME, Garcia-Basteiro, AL, Cambau, E, Chaisson, RE, Chee, CBE, Dalcolmo, MP, Denholm, JT, Erkens, C, Esposito, S, Farnia, P, Friedland, JS, Graham, S, Hamada, Y, Harries, AD, Kay, AW, Kritski, A, Manga, S, Marais, BJ, Menzies, D, Ng, D, Petrone, L, Rendon, A, Silva, DR, Schaaf, HS, Skrahina, A, Sotgiu, G, Thwaites, G, Tiberi, S, Tukvadze, N, Zellweger, J-P, Ambrosio, LD, Centis, R, and Ong, CWM

Abstract

BACKGROUND: Tuberculosis (TB) preventive therapy (TPT) decreases the risk of developing TB disease and its associated morbidity and mortality. The aim of these clinical standards is to guide the assessment, management of TB infection (TBI) and implementation of TPT.METHODS: A panel of global experts in the field of TB care was identified; 41 participated in a Delphi process. A 5-point Likert scale was used to score the initial standards. After rounds of revision, the document was approved with 100% agreement.RESULTS: Eight clinical standards were defined: Standard 1, all individuals belonging to at-risk groups for TB should undergo testing for TBI; Standard 2, all individual candidates for TPT (including caregivers of children) should undergo a counselling/health education session; Standard 3, testing for TBI: timing and test of choice should be optimised; Standard 4, TB disease should be excluded prior to initiation of TPT; Standard 5, all candidates for TPT should undergo a set of baseline examinations; Standard 6, all individuals initiating TPT should receive one of the recommended regimens; Standard 7, all individuals who have started TPT should be monitored; Standard 8, a TBI screening and testing register should be kept to inform the cascade of care.CONCLUSION: This is the first consensus-based set of Clinical Standards for TBI. This document guides clinicians, programme managers and public health officers in planning and implementing adequate measures to assess and manage TBI.

Published
2022

15. Clinical standards for the diagnosis, treatment and prevention of TB infection

Author

Migliori, G. B., primary, Wu, S. J., additional, Matteelli, A., additional, Zenner, D., additional, Goletti, D., additional, Ahmedov, S., additional, Al-Abri, S., additional, Allen, D. M., additional, Balcells, M. E., additional, Garcia-Basteiro, A. L., additional, Cambau, E., additional, Chaisson, R. E., additional, Chee, C. B. E., additional, Dalcolmo, M. P., additional, Denholm, J. T., additional, Erkens, C., additional, Esposito, S., additional, Farnia, P., additional, Friedland, J. S., additional, Graham, S., additional, Hamada, Y., additional, Harries, A. D., additional, Kay, A. W., additional, Kritski, A., additional, Manga, S., additional, Marais, B. J., additional, Menzies, D., additional, Ng, D., additional, Petrone, L., additional, Rendon, A., additional, Silva, D. R., additional, Schaaf, H. S., additional, Skrahina, A., additional, Sotgiu, G., additional, Thwaites, G., additional, Tiberi, S., additional, Tukvadze, N., additional, Zellweger, J.-P., additional, D´Ambrosio, L., additional, Centis, R., additional, and Ong, C. W. M., additional

Published
2022
Full Text
View/download PDF

17. Tuberculosis and COVID-19 co-infection: description of the global cohort

Author

Migliori, G. B., Casco, N., Jorge, A. L., Palmero, D. J., Alffenaar, J. -W., Denholm, J., Fox, G. J., Ezz, W., Cho, J. -G., Skrahina, A., Solodovnikova, V., Bachez, P., Piubello, A., Arbex, M. A., Alves, T., Rabahi, M. F., Pereira, G. R., Sales, R., Silva, D. R., Saffie, M. M., Miranda, R. C., Cancino, V., Carbonell, M., Cisterna, C., Concha, C., Cruz, A., Salinas, N. E., Revillot, M. E., Valdes, J. F., Fernandez, I., Flores, X., Tapia, P. G., Garavagno, A., Vera, C. G., Bahamondes, M. H., Merino, L. M., Munoz, E., Munoz, C., Navarro, I., Subiabre, J. N., Ortega, C., Palma, S., Pradenas, A. M., Pereira, G., Castillo, P. P., Pinto, M., Pizarro, R., Bidegain, F. R., Rodriguez, P., Sanchez, C., Salinas, A. S., Soto, A., Taiba, C., Venegas, M., Riquelme, M. S. V., Vilca, E., Villalon, C., Yucra, E., Li, Y., Guelvez, B., Plaza, R. V., Hoyos, K. Y. T., Andrejak, C., Blanc, F. -X., Dourmane, S., Froissart, A., Izadifar, A., Riviere, F., Schlemmer, F., Manika, K., Diallo, B. D., Hassane-Harouna, S., Artiles, N., Mejia, L. A., Gupta, N., Ish, P., Mishra, G., Sharma, S., Singla, R., Udwadia, Z. F., Alladio, F., Angeli, F., Calcagno, A., Centis, R., Codecasa, L. R., D'Ambrosio, L., De Lauretis, A., Esposito, S., Formenti, B., Gaviraghi, A., Giacomet, V., Goletti, D., Gualano, G., Matteelli, A., Motta, I., Palmieri, F., Pontali, E., Prestileo, T., Riccardi, N., Saderi, L., Saporiti, M., Sotgiu, G., Stochino, C., Tadolini, M., Torre, A., Villa, S., Visca, D., Danila, E., Diktanas, S., Ridaura, R. L., Lopez, F. L. L., Torrico, M. M., Rendon, A., Akkerman, O. W., Souleymane, M. B., Al-Abri, S., Alyaquobi, F., Althohli, K., Aizpurua, E., Gonzales, R., Jurado, J., Loban, A., Aguirre, S., Teixeira, R. C., De Egea, V., Irala, S., Medina, A., Sequera, G., Sosa, N., Vazquez, F., Llanos-Tejada, F. K., Manga, S., Villanueva-Villegas, R., Araujo, D., Duarte, R., Marques, T. S., Grecu, V. I., Socaci, A., Barkanova, O., Bogorodskaya, M., Borisov, S., Mariandyshev, A., Kaluzhenina, A., Vukicevic, T. A., Stosic, M., Beh, D., Ng, D., Ong, C. W. M., Solovic, I., Dheda, K., Gina, P., Caminero, J. A., Cardoso-Landivar, J., De Souza Galvao, M. L., Dominguez-Castellano, A., Garcia-Garcia, J. -M., Pinargote, I. M., Fernandez, S. Q., Sanchez-Montalva, A., Huguet, E. T., Murguiondo, M. Z., Bart, P. -A., Mazza-Stalder, J., Bakko, F., Barnacle, J., Brown, A., Chandran, S., Killington, K., Man, K., Papineni, P., Tiberi, S., Utjesanovic, N., Zenner, D., Hearn, J. L., Heysell, S., and Young, L.

Subjects
Pulmonary and Respiratory Medicine, Cohort Studies, Male, Coinfection, Humans, Prospective Studies, COVID-19, Tuberculosis, Original Research Article
Abstract

BackgroundInformation on tuberculosis (TB) and coronavirus disease 2019 (COVID-19) is still limited. The aim of this study was to describe the features of the TB/COVID-19 co-infected individuals from a prospective, anonymised, multicountry register-based cohort with special focus on the determinants of mortality and other outcomes.MethodsWe enrolled all patients of any age with either active TB or previous TB and COVID-19. 172 centres from 34 countries provided individual data on 767 TB-COVID-19 co-infected patients, (>50% population-based).ResultsOf 767 patients, 553 (74.0%) out of 747 had TB before COVID-19 (including 234 out of 747 with previous TB), 71 (9.5%) out of 747 had COVID-19 first and 123 (16.5%) out of 747 had both diseases diagnosed within the same week (n=35 (4.6%) on the same day). 85 (11.08%) out of 767 patients died (41 (14.2%) out of 289 in Europe and 44 (9.2%) out of 478 outside Europe; p=0.03): 42 (49.4%) from COVID-19, 31 (36.5%) from COVID-19 and TB, one (1.2%) from TB and 11 from other causes. In the univariate analysis on mortality the following variables reached statistical significance: age, male gender, having more than one comorbidity, diabetes mellitus, cardiovascular disease, chronic respiratory disease, chronic renal disease, presence of key symptoms, invasive ventilation and hospitalisation due to COVID-19. The final multivariable logistic regression model included age, male gender and invasive ventilation as independent contributors to mortality.ConclusionThe data suggest that TB and COVID-19 are a “cursed duet” and need immediate attention. TB should be considered a risk factor for severe COVID disease and patients with TB should be prioritised for COVID-19 preventative efforts, including vaccination.

Published
2021

19. Anomalies of coronary artery origin: About two cases

Author

Diop Ad, Bindia D, Manga S, Dioum M, Diagne Pa, Diack A, Joseph Salvador Mingou, Diop Ib, E. M. Sarr, and Sarr An

Subjects
medicine.medical_specialty, medicine.anatomical_structure, business.industry, Internal medicine, Cardiology, Medicine, business, Artery
Published
2019
Full Text
View/download PDF

20. TB and COVID-19 co-infection: rationale and aims of a global study

Author

Casco, N., Jorge, A. L., Palmero, D., Alffenaar, J. -W., Fox, G., Ezz, W., Cho, J. -G., Skrahina, A., Solodovnikova, V., Bachez, P., Arbex, M. A., Galvao, T., Rabahi, M., Pereira, G. R., Sales, R., Silva, D. R., Saffie, M. M., Miranda, R. C., Cancino, V., Carbonell, M., Cisterna, C., Concha, C., Cruz, A., Salinas, N. E., Revillot, M. E., Farias, J., Fernandez, I., Flores, X., Gallegos, P., Garavagno, A., Guajardo, C., Bahamondes, M. H., Merino, L. M., Munoz, E., Munoz, C., Navarro, I., Navarro, J., Ortega, C., Palma, S., Pardenas, A. M., Pereira, G., Castillo, P. P., Pinto, M., Pizarro, R., Rivas, F., Rodriguez, P., Sanchez, C., Serrano, A., Soto, A., Taiba, C., Venegas, M., Vergara, M. S., Vilca, E., Villalon, C., Yucra, E., Li, Y., Guelvez, B., Plaza, R., Tello, K., Andrejak, C., Blanc, F. -X., Dourmane, S., Froissart, A., Izadifar, A., Riviere, F., Schlemmer, F., Gupta, N., Ish, P., Mishra, G., Sharma, S., Singla, R., Udwadia, Z. F., Manika, K., Diallo, B. D., Hassane-Harouna, S., Artiles, N., Mejia, L. A., Alladio, F., Calcagno, A., Centis, R., Codecasa, L. R., D'Ambrosio, L., Formenti, B., Gaviraghi, A., Giacomet, V., Goletti, D., Gualano, G., Matteelli, A., Migliori, G. B., Motta, I., Palmieri, F., Prestileo, T., Riccardi, N., Saderi, L., Saporiti, M., Sotgiu, G., Stochino, C., Tadolini, M., Torre, A., Visca, D., Villa, S., Kuksa, L., Danila, E., Diktanas, S., Miliauskas, S., Ridaura, R. L., Lopez, F. L. L., Torrico, M. M., Rendon, A., Akkerman, O. W., Piubello, A., Souleymane, M. B., Aizpurua, E., Gonzales, R., Jurado, J., Loban, A., Aguirre, S., De Egea, V., Irala, S., Medina, A., Sequera, G., Sosa, N., Vazquez, F., Manga, S., Villanueva, R., Araujo, D., Duarte, R., Marques, T. S., Grecu, V. I., Socaci, A., Barkanova, O., Bogorodskaya, M., Borisov, S., Mariandyshev, A., Kaluzhenina, A., Stosic, M., Beh, D., Ng, D., Ong, C. W. M., Solovic, I., Dheda, D., Gina, P., Caminero, J. A., Cardoso-Landivar, J., De Souza Galvao, M. L., Dominguez-Castellano, A., Garcia-Garcia, J. -M., Pinargote, I. M., Fernandez, S. Q., Sanchez-Montalva, A., Huguet, E. T., Murguiondo, M. Z., Bruchfeld, J., Bart, P. -A., Mazza-Stalder, J., Tiberi, S., Arrieta, F., Heysell, S., Logsdon, J., Young, L., Department of Physics [Glasgow], University of Strathclyde [Glasgow], Instituto de Fisica Corpuscular (IFIC), Consejo Superior de Investigaciones Científicas [Madrid] (CSIC)-Universitat de València (UV), Laboratoire d'Etude des Mécanismes Cognitifs (EMC), Université Lumière - Lyon 2 (UL2), Added Value Solutions (AVS), Universidade de Santiago de Compostela [Spain] (USC ), Departamento de Ingeniería Térmica y de Fluidos, Avda. Universidad 30, University Medical Center Göttingen (UMG), CHU Amiens-Picardie, Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 (AGIR ), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Réanimation Médicale [CHU Henri Mondor - APHP] (DHU A-TVB), CHU Henri Mondor-Université Paris-Est Créteil, Faculté de Médecine [Créteil] (UPEC-Médecine), Inter-University Centre for Astronomy and Astrophysics [Pune] (IUCAA), Alma Mater Studiorum University of Bologna (UNIBO), Laboratoire des EcoSystèmes et des Sociétés en Montagne (UR LESSEM), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Università degli Studi di Milano = University of Milan (UNIMI), Vilnius University [Vilnius], Instituto de Ciencias Nucleares [Mexico], Universidad Nacional Autónoma de México = National Autonomous University of Mexico (UNAM), Instituto Mexicano del Petróleo (IMP), University of Cadiz, Hospital Universitario Puerta de Hierro-Majadahonda [Madrid, Spain], Bart's and The London School of Medicine and Dentistry, Queen Mary University of London (QMUL), Southwest Research Institute [Boulder] (SwRI), BIOLOGICAL AND AGRICULTURAL ENGINEERING NORTH CAROLINA STATE UNIVERSITY RALEIGH USA, Partenaires IRSTEA, Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA)-Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA), Microbes in Health and Disease (MHD), Université Paris-Est Créteil, Faculté de Médecine [Créteil] (UPEC-Médecine)-CHU Henri Mondor, Università degli Studi di Milano [Milano] (UNIMI), and Universidad Nacional Autónoma de México (UNAM)

Subjects
Pulmonary and Respiratory Medicine, Research design, medicine.medical_specialty, Tuberculosis, Coronavirus disease 2019 (COVID-19), [SDV]Life Sciences [q-bio], MEDLINE, Global Health, medicine, Global health, Humans, Multicenter Studies as Topic, Prospective Studies, Intensive care medicine, Prospective cohort study, Tuberculosis, Pulmonary, ComputingMilieux_MISCELLANEOUS, business.industry, Coinfection, COVID-19, Pulmonary, medicine.disease, Infectious Diseases, Research Design, business, Co infection
Abstract

International audience

Published
2021
Full Text
View/download PDF

21. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort

Author

Koirala, S, Borisov, S, Danila, E, Mariandyshev, A, Shrestha, B, Lukhele, N, Dalcolmo, M, Shakya, SR, Miliauskas, S, Kuksa, L, Manga, S, Aleksa, A, Denholm, JT, Khadka, HB, Skrahina, A, Diktanas, S, Ferrarese, M, Bruchfeld, J, Koleva, A, Piubello, A, Koirala, GS, Udwadia, ZF, Palmero, DJ, Munoz-Torrico, M, Gc, R, Gualano, G, Grecu, V, Motta, I, Papavasileiou, A, Li, Y, Hoefsloot, W, Kunst, H, Mazza-Stalder, J, Payen, M-C, Akkerman, OW, Bernal, E, Manfrin, V, Matteelli, A, Hamdan, HM, Marcos, MN, Cadinanos Loidi, J, Cebrian Gallardo, JJ, Duarte, R, Escobar Salinas, N, Gomez Rosso, R, Laniado-Laborin, R, Martinez Robles, E, Quiros Fernandez, S, Rendon, A, Solovic, I, Tadolini, M, Viggiani, P, Belilovski, E, Boeree, MJ, Cai, Q, Davidaviciene, E, Forsman, LD, De Los Rios, J, Draksiene, J, Duga, A, Elamin, SE, Filippov, A, Garcia, A, Gaudiesiute, I, Gavazova, B, Gayoso, R, Gruslys, V, Jonsson, J, Khimova, E, Madonsela, G, Magis-Escurra, C, Marchese, V, Matei, M, Moschos, C, Nakceriene, B, Nicod, L, Palmieri, F, Pontarelli, A, Smite, A, Souleymane, MB, Vescovo, M, Zablockis, R, Zhurkin, D, Alffenaar, J-W, Caminero, JA, Codecasa, LR, Garcia-Garcia, J-M, Esposito, S, Saderi, L, Spanevello, A, Visca, D, Tiberi, S, Pontali, E, Centis, R, D'Ambrosio, L, van den Boom, M, Sotgiuw, G, Migliori, GB, Koirala, S, Borisov, S, Danila, E, Mariandyshev, A, Shrestha, B, Lukhele, N, Dalcolmo, M, Shakya, SR, Miliauskas, S, Kuksa, L, Manga, S, Aleksa, A, Denholm, JT, Khadka, HB, Skrahina, A, Diktanas, S, Ferrarese, M, Bruchfeld, J, Koleva, A, Piubello, A, Koirala, GS, Udwadia, ZF, Palmero, DJ, Munoz-Torrico, M, Gc, R, Gualano, G, Grecu, V, Motta, I, Papavasileiou, A, Li, Y, Hoefsloot, W, Kunst, H, Mazza-Stalder, J, Payen, M-C, Akkerman, OW, Bernal, E, Manfrin, V, Matteelli, A, Hamdan, HM, Marcos, MN, Cadinanos Loidi, J, Cebrian Gallardo, JJ, Duarte, R, Escobar Salinas, N, Gomez Rosso, R, Laniado-Laborin, R, Martinez Robles, E, Quiros Fernandez, S, Rendon, A, Solovic, I, Tadolini, M, Viggiani, P, Belilovski, E, Boeree, MJ, Cai, Q, Davidaviciene, E, Forsman, LD, De Los Rios, J, Draksiene, J, Duga, A, Elamin, SE, Filippov, A, Garcia, A, Gaudiesiute, I, Gavazova, B, Gayoso, R, Gruslys, V, Jonsson, J, Khimova, E, Madonsela, G, Magis-Escurra, C, Marchese, V, Matei, M, Moschos, C, Nakceriene, B, Nicod, L, Palmieri, F, Pontarelli, A, Smite, A, Souleymane, MB, Vescovo, M, Zablockis, R, Zhurkin, D, Alffenaar, J-W, Caminero, JA, Codecasa, LR, Garcia-Garcia, J-M, Esposito, S, Saderi, L, Spanevello, A, Visca, D, Tiberi, S, Pontali, E, Centis, R, D'Ambrosio, L, van den Boom, M, Sotgiuw, G, and Migliori, GB

Abstract

The World Health Organization (WHO) recommends countries introduce new anti-TB drugs in the treatment of multidrug-resistant tuberculosis. The aim of the study is to prospectively evaluate the effectiveness of bedaquiline (and/or delamanid)- containing regimens in a large cohort of consecutive TB patients treated globally. This observational, prospective study is based on data collected and provided by Global Tuberculosis Network (GTN) centres and analysed twice a year. All consecutive patients (including children/adolescents) treated with bedaquiline and/or delamanid were enrolled, and managed according to WHO and national guidelines. Overall, 52 centres from 29 countries/regions in all continents reported 883 patients as of January 31st 2021, 24/29 countries/regions providing data on 100% of their consecutive patients (10-80% in the remaining 5 countries). The drug-resistance pattern of the patients was severe (>30% with extensively drug-resistant -TB; median number of resistant drugs 5 (3-7) in the overall cohort and 6 (4-8) among patients with a final outcome). For the patients with a final outcome (477/883, 54.0%) the median (IQR) number of months of anti-TB treatment was 18 (13-23) (in days 553 (385-678)). The proportion of patients achieving sputum smear and culture conversion ranged from 93.4% and 92.8% respectively (whole cohort) to 89.3% and 88.8% respectively (patients with a final outcome), a median (IQR) time to sputum smear and culture conversion of 58 (30-90) days for the whole cohort and 60 (30-100) for patients with a final outcome and, respectively, of 55 (30-90) and 60 (30-90) days for culture conversion. Of 383 patients treated with bedaquiline but not delamanid, 284 (74.2%) achieved treatment success, while 25 (6.5%) died, 11 (2.9%) failed and 63 (16.5%) were lost to follow-up.

Published
2021

22. Screening for Tuberculosis in Migrants: A Survey by the Global Tuberculosis Network

Author

D'Ambrosio, L, Centis, R, Dobler, CC, Tiberi, S, Matteelli, A, Denholm, J, Zenner, D, Al-Abri, S, Alyaquobi, F, Arbex, MA, Belilovskiy, E, Blanc, F-X, Borisov, S, Carvalho, ACC, Chakaya, JM, Cocco, N, Codecasa, LR, Dalcolmo, MP, Dheda, K, Dinh-Xuan, AT, Esposito, SR, Garcia-Garcia, J-M, Li, Y, Manga, S, Marchese, V, Munoz Torrico, M, Pontali, E, Rendon, A, Rossato Silva, D, Singla, R, Solovic, I, Sotgiu, G, van den Boom, M, Nhung, NV, Zellweger, J-P, Migliori, GB, D'Ambrosio, L, Centis, R, Dobler, CC, Tiberi, S, Matteelli, A, Denholm, J, Zenner, D, Al-Abri, S, Alyaquobi, F, Arbex, MA, Belilovskiy, E, Blanc, F-X, Borisov, S, Carvalho, ACC, Chakaya, JM, Cocco, N, Codecasa, LR, Dalcolmo, MP, Dheda, K, Dinh-Xuan, AT, Esposito, SR, Garcia-Garcia, J-M, Li, Y, Manga, S, Marchese, V, Munoz Torrico, M, Pontali, E, Rendon, A, Rossato Silva, D, Singla, R, Solovic, I, Sotgiu, G, van den Boom, M, Nhung, NV, Zellweger, J-P, and Migliori, GB

Abstract

Tuberculosis (TB) does not respect borders, and migration confounds global TB control and elimination. Systematic screening of immigrants from TB high burden settings and-to a lesser degree TB infection (TBI)-is recommended in most countries with a low incidence of TB. The aim of the study was to evaluate the views of a diverse group of international health professionals on TB management among migrants. Participants expressed their level of agreement using a six-point Likert scale with different statements in an online survey available in English, French, Mandarin, Spanish, Portuguese and Russian. The survey consisted of eight sections, covering TB and TBI screening and treatment in migrants. A total of 1055 respondents from 80 countries and territories participated between November 2019 and April 2020. The largest professional groups were pulmonologists (16.8%), other clinicians (30.4%), and nurses (11.8%). Participants generally supported infection control and TB surveillance established practices (administrative interventions, personal protection, etc.), while they disagreed on how to diagnose and manage both TB and TBI, particularly on which TBI regimens to use and when patients should be hospitalised. The results of this first knowledge, attitude and practice study on TB screening and treatment in migrants will inform public health policy and educational resources.

Published
2021

31. Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?

Author

Alffenaar, J. -W. C., Akkerman, O. W., Tiberi, S., Sotgiu, G., Migliori, G. B., Montaner, P. G., Palmero, D. J., Denholm, J., Douglas, P., Lau, J. S., Tramontana, A. R., Aleksa, A., Artsukevich, J., Sanukevich, T., Skrahina, A., Solodovnikova, V., Payen, M. -C., Dalcolmo, M., Gaga, M., Manika, K., Papavasileiou, A., Amale, R., Ganatra, S., Mullerpattan, J., Sadutshang, T. D., Topgyal, S., Udwadia, Z. F., Centis, R., Codecasa, L., D'Ambrosio, L., Gualano, G., Palmieri, F., Papalia, A., Pontali, E., Saderi, L., Spanevello, A., Toscanini, F., Viggiani, P., Manga, S., Duarte, R., Cordeiro, C. R., Belilovski, E., Borisov, S. E., Filippov, A., Maryandyshev, A., Dheda, K., Enwerem, M., Esmail, A., Fadul, M., Mastrapa, B. L., Teran Troya, J. L., Oelofse, S., Leyet, R. R., Caminero, J. A., Garcia-Garcia, J. -M., Garcia-Fuertes, J. -A., Martinez, I. C., Bruchfeld, J., Forsman, L. D., Jonsson, J., Kunst, H., White, V., and Zumla, A.

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Standard of care, media_common.quotation_subject, Extensively Drug-Resistant Tuberculosis, Antitubercular Agents, World health, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Nothing, Tuberculosis, Multidrug-Resistant, Medicine, Humans, 030212 general & internal medicine, Diarylquinolines, Intensive care medicine, media_common, business.industry, Conflict of interest, Guideline, Precision medicine, 030228 respiratory system, chemistry, Worry, Bedaquiline, business
Abstract

Recently, the World Health Organization (WHO) released the updated guideline on the treatment for multi-drug resistant tuberculosis (MDR-TB) treatment regimens based on new experimental and observational evidence [1]. In this new guidance the most important drugs are the late-generation fluoroquinolones ( i.e. , levofloxacin and moxifloxacin), linezolid, and bedaquiline. Despite the new guidance MDR- and extensively drug resistant (XDR) TB treatment is challenging due to the risk of drug-related adverse events (AE) and drug-drug interactions (DDI). Precision medicine-based approach to minimise the risk of resistance emergence and amplification and to provide patients with the highest standard of care has been recommended [2]. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of interest: Dr. Alffenaar has nothing to disclose. Conflict of interest: Dr. Akkerman has nothing to disclose. Conflict of interest: Dr. Tiberi has nothing to disclose. Conflict of interest: Dr. Sotgiu has nothing to disclose. Conflict of interest: Dr. Migliori has nothing to disclose.

Published
2019

32. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report

Author

Borisov, S., Danila, E., Maryandyshev, A., Dalcolmo, M., Miliauskas, S., Kuksa, L., Manga, S., Skrahina, A., Diktanas, S., Codecasa, L.R., Aleksa, A., Bruchfeld, J., Koleva, A., Piubello, A., Udwadia, Z.F., Akkerman, O.W., Belilovski, E., Bernal, E., Boeree, M.J., Loidi, J., Cai, Q., Gallardo, J.J. Cebrian, Dara, M., Davidaviciene, E., Forsman, L.D., Rios, J. De Los, Denholm, J., Draksiene, J., Duarte, R., Elamin, S.E., Salinas, N. Escobar, Ferrarese, M., Filippov, A., Garcia, A., Garcia-Garcia, J.M., Gaudiesiute, I., Gavazova, B., Gayoso, R., Rosso, R., Gruslys, V., Gualano, G., Hoefsloot, W., Jonsson, J., Khimova, E., Kunst, H., Laniado-Laborin, R., Li, Y, Magis-Escurra, C., Manfrin, V., Marchese, V., Robles, E. Martinez, Matteelli, A., Mazza-Stalder, J., Moschos, C., Munoz-Torrico, M., Hamdan, H. Mustafa, Nakceriene, B., Nicod, L., Marcos, M., Palmero, D.J., Palmieri, F., Papavasileiou, A., Payen, M.C., Pontarelli, A., Quiros, S., Rendon, A., Saderi, L., Smite, A., Solovic, I., Souleymane, M.B., Tadolini, M., Boom, M. van den, Vescovo, M., Viggiani, P., Yedilbayev, A., Zablockis, R., Zhurkin, D., Zignol, M., Visca, D., Spanevello, A., Caminero, J.A., Alffenaar, J.W.C., Tiberi, S., Centis, R., D'Ambrosio, L., Pontali, E., Sotgiu, G., Migliori, G.B., Borisov, S., Danila, E., Maryandyshev, A., Dalcolmo, M., Miliauskas, S., Kuksa, L., Manga, S., Skrahina, A., Diktanas, S., Codecasa, L.R., Aleksa, A., Bruchfeld, J., Koleva, A., Piubello, A., Udwadia, Z.F., Akkerman, O.W., Belilovski, E., Bernal, E., Boeree, M.J., Loidi, J., Cai, Q., Gallardo, J.J. Cebrian, Dara, M., Davidaviciene, E., Forsman, L.D., Rios, J. De Los, Denholm, J., Draksiene, J., Duarte, R., Elamin, S.E., Salinas, N. Escobar, Ferrarese, M., Filippov, A., Garcia, A., Garcia-Garcia, J.M., Gaudiesiute, I., Gavazova, B., Gayoso, R., Rosso, R., Gruslys, V., Gualano, G., Hoefsloot, W., Jonsson, J., Khimova, E., Kunst, H., Laniado-Laborin, R., Li, Y, Magis-Escurra, C., Manfrin, V., Marchese, V., Robles, E. Martinez, Matteelli, A., Mazza-Stalder, J., Moschos, C., Munoz-Torrico, M., Hamdan, H. Mustafa, Nakceriene, B., Nicod, L., Marcos, M., Palmero, D.J., Palmieri, F., Papavasileiou, A., Payen, M.C., Pontarelli, A., Quiros, S., Rendon, A., Saderi, L., Smite, A., Solovic, I., Souleymane, M.B., Tadolini, M., Boom, M. van den, Vescovo, M., Viggiani, P., Yedilbayev, A., Zablockis, R., Zhurkin, D., Zignol, M., Visca, D., Spanevello, A., Caminero, J.A., Alffenaar, J.W.C., Tiberi, S., Centis, R., D'Ambrosio, L., Pontali, E., Sotgiu, G., and Migliori, G.B.

Abstract

Item does not contain fulltext, The World Health Organization (WHO) recommends that countries implement pharmacovigilance and collect information on active drug safety monitoring (aDSM) and management of adverse events.The aim of this prospective study was to evaluate the frequency and severity of adverse events to anti-tuberculosis (TB) drugs in a cohort of consecutive TB patients treated with new (i.e. bedaquiline, delamanid) and repurposed (i.e. clofazimine, linezolid) drugs, based on the WHO aDSM project. Adverse events were collected prospectively after attribution to a specific drug together with demographic, bacteriological, radiological and clinical information at diagnosis and during therapy. This interim analysis included patients who completed or were still on treatment at time of data collection.Globally, 45 centres from 26 countries/regions reported 658 patients (68.7% male, 4.4% HIV co-infected) treated as follows: 87.7% with bedaquiline, 18.4% with delamanid (6.1% with both), 81.5% with linezolid and 32.4% with clofazimine. Overall, 504 adverse event episodes were reported: 447 (88.7%) were classified as minor (grade 1-2) and 57 (11.3%) as serious (grade 3-5). The majority of the 57 serious adverse events reported by 55 patients (51 out of 57, 89.5%) ultimately resolved. Among patients reporting serious adverse events, some drugs held responsible were discontinued: bedaquiline in 0.35% (two out of 577), delamanid in 0.8% (one out of 121), linezolid in 1.9% (10 out of 536) and clofazimine in 1.4% (three out of 213) of patients. Serious adverse events were reported in 6.9% (nine out of 131) of patients treated with amikacin, 0.4% (one out of 221) with ethionamide/prothionamide, 2.8% (15 out of 536) with linezolid and 1.8% (eight out of 498) with cycloserine/terizidone.The aDSM study provided valuable information, but implementation needs scaling-up to support patient-centred care.

Published
2019

33. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study

Author

Akkerman, O., Aleksa, A., Alffenaar, J.W.C., Al-Marzouqi, N.H., Arias-Guillen, M., Belilovski, E., Bernal, E., Boeree, M.J., Borisov, S.E., Bruchfeld, J., Loidi, J., Cai, Q., Caminero, J.A., Gallardo, J.J. Cebrian, Centis, R., Codecasa, L.R., D'Ambrosio, L., Dalcolmo, M., Danila, E., Dara, M., Davidaviciene, E., Forsman, L. Davies, Jefe, J. De Los Rios, Denholm, J., Duarte, R., Elamin, S.E., Ferrarese, M., Filippov, A., Ganatra, S., Garcia, A., Garcia-Garcia, J.M., Gayoso, R., Montoya, A.M. Giraldo, Rosso, R.G. Gomez, Gualano, G., Hoefsloot, W., Ilievska-Poposka, B., Jonsson, J., Khimova, E., Kuksa, L., Kunst, H., Laniado-Laborin, R., Li, Y., Magis-Escurra, C., Manfrin, V., Manga, S., Marchese, V., Robles, E. Martinez, Maryandyshev, A., Matteelli, A., Migliori, G.B., Mullerpattan, J.B., Munoz-Torrico, M., Hamdan, H. Mustafa, Marcos, M., Noordin, N.M., Palmero, D.J., Palmieri, F., Payen, M.C., Piubello, A., Pontali, E., Pontarelli, A., Quiros, S., Rendon, A., Skrahina, A., Smite, A., Solovic, I., Sotgiu, G., Souleymane, M.B., Spanevello, A., Stosic, M., Tadolini, M., Tiberi, S., Udwadia, Z.F., Boom, M. van den, Vescovo, M., Viggiani, P., Visca, D., Zhurkin, D., Zignol, M., Akkerman, O., Aleksa, A., Alffenaar, J.W.C., Al-Marzouqi, N.H., Arias-Guillen, M., Belilovski, E., Bernal, E., Boeree, M.J., Borisov, S.E., Bruchfeld, J., Loidi, J., Cai, Q., Caminero, J.A., Gallardo, J.J. Cebrian, Centis, R., Codecasa, L.R., D'Ambrosio, L., Dalcolmo, M., Danila, E., Dara, M., Davidaviciene, E., Forsman, L. Davies, Jefe, J. De Los Rios, Denholm, J., Duarte, R., Elamin, S.E., Ferrarese, M., Filippov, A., Ganatra, S., Garcia, A., Garcia-Garcia, J.M., Gayoso, R., Montoya, A.M. Giraldo, Rosso, R.G. Gomez, Gualano, G., Hoefsloot, W., Ilievska-Poposka, B., Jonsson, J., Khimova, E., Kuksa, L., Kunst, H., Laniado-Laborin, R., Li, Y., Magis-Escurra, C., Manfrin, V., Manga, S., Marchese, V., Robles, E. Martinez, Maryandyshev, A., Matteelli, A., Migliori, G.B., Mullerpattan, J.B., Munoz-Torrico, M., Hamdan, H. Mustafa, Marcos, M., Noordin, N.M., Palmero, D.J., Palmieri, F., Payen, M.C., Piubello, A., Pontali, E., Pontarelli, A., Quiros, S., Rendon, A., Skrahina, A., Smite, A., Solovic, I., Sotgiu, G., Souleymane, M.B., Spanevello, A., Stosic, M., Tadolini, M., Tiberi, S., Udwadia, Z.F., Boom, M. van den, Vescovo, M., Viggiani, P., Visca, D., Zhurkin, D., and Zignol, M.

Abstract

Contains fulltext : 207083.pdf (publisher's version ) (Open Access), The World Health Organization launched a global initiative, known as aDSM (active TB drug safety monitoring and management) to better describe the safety profile of new treatment regimens for drug-resistant tuberculosis (TB) in real-world settings. However, comprehensive surveillance is difficult to implement in several countries. The aim of the aDSM project is to demonstrate the feasibility of implementing national aDSM registers and to describe the type and the frequency of adverse events (AEs) associated with exposure to the new anti-TB drugs. Following a pilot study carried out in 2016, official involvement of TB reference centres/countries into the project was sought and cases treated with bedaquiline- and/or delamanid-containing regimens were consecutively recruited. AEs were prospectively collected ensuring potential attribution of the AE to a specific drug based on its known safety profile. A total of 309 cases were fully reported from 41 centres in 27 countries (65% males; 268 treated with bedaquiline, 20 with delamanid, and 21 with both drugs) out of an estimated 781 cases the participating countries had committed to report by the first quarter of 2019.

Published
2019

34. Prevalence of Staphylococcus aureus in some street vended ready-to-eat meat products in Birnin Kebbi metropolis: A potential food safety threat

Author

Ribah, M. I. and Manga, S. S.

Subjects
Staphylococcus aureus, food safety threat, prevalence, ready-to-eat meat products
Abstract

This study was designed to determine the prevalence of Staphylococcus aureus in Street vended Balangu, Kilishi and Tsire meat products in Birnin kebbi, Kebbi State, Nigeria. Sixty six (66) samples (tsire–21, Kilishi-21 and Balangu-24), were purchased from street vendors and transferred for microbiological analyses. Microbiological analyses were conducted according to standard culture procedure involving isolation in general and selective media for isolation and identification of isolates, followed by series of biochemical tests for confirmation of isolates. Data was analyzed and expressed as colony forming units per gram of sample (cfu/g). Results revealed bacterial load and presence of Staphylococcus aureus isolated from the RTE-MPs. The total bacterial counts for tsire, balangu and kilishi were found to be 1.34, 1.71 and 2.01×106 cfu/g, respectively. Also, the Staphylococcus aureus population isolated from tsire, balangu and kilishi were recorded as 0.14, 0.29 and 0.33×104 cfu/g, respectively. In terms of public health significance, the results of the current study placed the studied RTE-MPs consumed in the study area within unsatisfactory limits since the values are more than log 9×106 recommended to be acceptable in related RTE-MPs. However, the value for Staphylococcus aureus was satisfactory since it was found to be within the limits of 4cfu/g recommended be the satisfactory limits for consumption. It was concluded that the high bacterial count observed and the presence of Staphylococcus aureus in the RTE-MPs are of public health significance since they could pose health risks. Good manufacturing practices in the production and consumption of RTE-MPs were recommended to improve their safety and quality.

Published
2018
Full Text
View/download PDF

40. Production of L-Arginine Using Wastes of Carica Papaya and Ananas Comosus by Pediococcus Pentosaceous

Author

Sarvamangala Dhurjeti, Kantipriya Kondala, Manga S, Neelima Mokara, Sudhakar Konada, and Sudesh Kumar Edavana

Subjects
chemistry.chemical_classification, biology, Chemistry, biology.organism_classification, chemistry.chemical_compound, Reagent, Ninhydrin, Botany, Fermentation, Pediococcus, Food science, Aeration, Carica, Ananas, Essential amino acid
Abstract

The present study was an illustrative investigation on the production of one of the essential amino acid L-arginine using two different wastes (Carica Papaya and Ananas Comosus) as substrates. An aerobic fermentative process was followed for the production by the bacteria Pediococcus Pentosaceous. The optimal characteristics temperature, fermentation time and pH for the maximum production were assayed. The quality of L-arginine was analysed by Kossel method and Arginine Dihydrolase Test and quantitative estimation was done by using ninhydrin reagent. From the investigations, an optimum temperature at 30°C with pH 9 and aeration were found to be suitable for max production in 5 days using both the substrates (0.54 mg/ml) (0.675 mg/ml) waste media.

Published
2015
Full Text
View/download PDF

41. ANTIBACTERIAL ACTIVITY AND TOXICOLOGICAL EVALUATION OF Anogeissusieiocarpus AND Psidium guajava ON Escherichia coli and Staphylococcus aureus.

Author

Yabo, S. A., Manga, S. B., Baki, A. S., Atata, R. F., Gambo, S., and Tahir, H.

Subjects
GUAVA, STAPHYLOCOCCUS aureus, ESCHERICHIA coli, ANTIBACTERIAL agents, ACUTE toxicity testing
Abstract

The study was carried out to determine the antibacterial activities and toxicological evaluation of Anogeissusleiocarpus and Psidiumguajava on Escherichia coli and Staphylococcus aureus isolated from clinical samples. The plants leaves were extracted using Hexane, Methanol, Ethanol and Water. Various concentrations (50, 25, 12.5 and 6.25mg/ml) of the crude extract of the plants were prepared and their antibacterial activity against Staphylococcus aureus and E. coli was determined using Agar well (Diffusion) method. Toxicity of the plants was evaluated, acute toxicity test, kidney and liver function tests. The result revealed that at 50mg/ml concentration, the leaf extract of Psidiumguajava was active against Staphylococcus aureus and E. coliexhibiting the highest zones of inhibition of 19mm and 9mm respectively. Whereas The leaf extract of Anogeissusleiocarpus only inhibited the growth of Staphylococcus aureus recording highest zone of inhibition of 15mm at a concentration of 50mg/ml. The plant extracts were found to be non-toxic as the LD50 was above 5000mg/kg and the biochemical parameters evaluated for both liver and kidney function tests revealed values that are within normal range. Hence the study established that consumption of the leaves of P. guajava for medicinal purpose can be said to be innocuous, as such the plant could be regarded as a potential candidate in the search of potent and harmless plants of therapeutic value. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

43. SYNTHESIS, CHARACTERIZATION AND ANTI MICROBIAL STUDIES OF AgNP’S USING PROBIOTICS

Author

D Sarvamangala, Kantipriya Kondala, N Sivakumar, M Saratchandra Babu, and Manga S

Subjects
Aqueous solution, Materials science, Absorption spectroscopy, Transmission electron microscopy, Silver Nano, Nanoparticle, Absorption (chemistry), Silver nanoparticle, Microbiology, Characterization (materials science), Nuclear chemistry
Abstract

Recent researches speak about the utilization of biological systems especially enterobacteri a to synthesize nanoparticles is a novel approach. The present study demonstrates an eco - friendly and low cost protocol for synthesis of silver nano particles using the cell free filtrate of Lactobacillus bulgaricus when supplied with aqueous silver ions. Characterization of silver nanoparticles was done by UV - Visible absorption spectroscopy shows maximum absorption at 420 nm, Transmission electron microscope (TEM) revealed the formation of spherical nanoparticles with size ranging between 40 – 50nm, X - Ray diffraction (XRD) pattern shows spectrum, which reveals the FCC structure of silver nanoparticles. Energy dispersive spectroscope (EDS) analysi s was done using SEM instrument equipped with thermo EDS attachment shows the optical absorption peak at 3kev. Mi crobial nanoparticles showed very strong inhibitory action against Staphylococcus aureus, Staphylococcus albus, & Pseudomonas aeruginosa.

Published
2013
Full Text
View/download PDF

47. ISOLATION AND CHARACTERIZATION OF PARTIALLY FURIFIED BACTERIOCIN OF Bacillus cereus (CF1) SOIL ISOLATE.

Author

Bala, I., Arzai, A. H., Mukhtar, M. D., and Manga, S. B.

Subjects
BACILLUS cereus, MOLECULAR conformation, GEL electrophoresis, SOILS, SOIL sampling, UREA as fertilizer, BACTERIOCINS
Abstract

Bacteriocins are proteinaceous antimicrobial substances produce by bacteria against closely related bacterial species. However their broad spectrum inhibitory activity has been observed against other microorganisms such as fungi. The aim of this study was to isolate and determine physical, chemical and biological characteristics of bacteriocin from B. cereus of soil origin. A Gram-positive spore forming bacilli coded as CF1 was isolated by pour plating technique from the soil sample of the cereal farm land of Kura local government area, Kano State Nigeria and identified as Bacillus cereus based on cultural, microscopic and biochemical characteristics. Bacteriocin was isolated from this B. cereus and partially purified by solvent method (cold acetone) and had broad spectrum inhibitory activity with MIC of 64 AU/ml. This bacteriocin was thermo stable up to 121°C for 15 minutes and its activity was maintained at wider pH value of 2-12. Although, the bacteriocin isolated by this B. cereus was not affected by some chemical such as Urea, EDTA and Tween 80, other chemical such as SDS and trypsin enzyme deactivated its activity. It is therefore recommended that further studies be carryout on this bacteriocin to purify the bacteriocin using Poly Acryl Amide Gel Electrophoresis PAGE and to elucidate its sequence, to determine its molecular conformation and antibacterial activity on multi drug resistant pathogens. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

48. Cervical Cancer in Cameroon: A Three Pronged Approach to Increase Awareness, Vaccination, Screening and Treatment

Author

Ogembo, Javier Gordon, Muffih, T. P., Maranda, Louise, Wamai, R., Kemunto, R., Welty, E., Welty, T., Manga, S., Bradford, L., Kalmakis, K., and Sheldon, L. K.

Abstract

Problem: Cameroon has a disproportionately high burden of cervical cancer due to low awareness that the disease is preventable with prophylactic vaccines, lack of screening and treatment of pre-cancerous lesions, and high prevalence of human immunodeficiency virus (HIV). Between 2007-2013, the Cameroon Baptist Convention Health Services (CBCHS) devised three programs to: (1) increase awareness about cervical cancer; (2) immunize girls aged 9-13 years against human papilloma virus (HPV); and (3) conduct cervical cancer screening and treatment. Approaches: In collaboration with clinicians and researchers at University of Massachusetts and Northeastern University, CBCHS conducted education programs about HPV vaccine and cervical cancer for parents, adolescents, health care workers, and community members. The HPV vaccination demonstration project was implemented in three settings: schools, healthcare facilities, and in communities. CBCHS conducted cervical cancer screening in six sites using a “see and treat approach”. Findings: Following approval by the Ministry of Health, CBCHS nurses educated girls, parents, and communities about HPV, cervical cancer, and HPV vaccine through multimedia coverage. A total of 6,851, 6,517 and 5,876 girls were immunized with first, second and third doses, respectively. Achieving an 84.6% 3-dose completion rate. Since 2007, 30,617 women have been screened with visual inspection with acetic acid and digital cervicography. Women with precancerous lesions were treated with cryotherapy or loop electrical excision procedure. Lesions suspicious for cancer were biopsied for histology. Of those screened, 3,015 (10%) self reported HIV-positivity, 19,837 (64%) were HIV-negative, and the HIV status of the remaining women was unreported (25%). The percentage of HIV infected women diagnosed with cancer was consistently higher than the percentage of HIV uninfected women diagnosed with cancer. Lessons Learned: The project demonstrated that, with adequate education of stakeholders, HPV vaccination and cervical cancer screening programs are acceptable and feasible methods to improve cervical cancer outcomes in Cameroon.

Published
2014
Full Text
View/download PDF

49. Antimicrobial activity of Bis-salicylaldehyde Ethylenediamine Schiff Base and Its Lanthanoids (III) Complexes

Author

Mahmud, S.D., Birnin-Yauri, U.A., Liman, M.G., and Manga, S.B.

Subjects
Bis-salicylaldehyde ethylenediamine, Schiff base, Lanthanoids, antibacterial, antifungal, activity, Microbiology, QR1-502
Abstract

Schiff base readily form complex with metal ions and the resultant complexes especially from transition metals were extensively used in many fields of human endeavor including antimicrobial therapy. However, the potentials of Lanthanide-Schiff base complexes as an antimicrobial agent have not been adequately studied. This study aims to synthesize and determine the antimicrobial activity of Bis-salicylaldehyde ethylenediamine Schiff Base and its Lanthanoids (III) Complexes. The Dysprosium (III), Gadolinium (III), Neodymium (III) and Samarium (III) complexes of Schiff base derived from Salicylaldehyde and ethylenediamine were synthesized under reflux condition in ethanol and their antimicrobial activity were determined using disc diffusion method. Bis-salicylaldehyde ethylenediamine was a shiny crystalline yellow with a yield of 93% and its complexes were various sheds of yellow ranges from pale to dark, with percentage yield between 94-98%. The Bis-salicylaldehyde ethylenediamine had good activity against C. albican (32mm at 100mg/ml), A. niger (20mm at 100mg/ml) and Fusarium Spp (17mm at 100mg/ml) but its complexes had low (07-11mm at 100mg/ml) or no (06mm at 100mg/ml) activity against all the fungal isolates. The antibacterial activity of the Bis-salicylaldehyde ethylenediamine against E. coli (8mm at 100mg/ml), Pseudomonas (6mm at 100mg/ml) and Klebsiella (13mm at 100mg/ml) was lower than that of Ampiclox (between 17 to 20mm) and even though, all its Lanthanoid (III) complexes between 8 to 14mm at 100mg/ml) had higher antibacterial activity than the Bis-salicylaldehydeethylenediamine but still the activity of Lanthanoid (III) complexes was lower than that of Ampiclox. Considering the in-vitro antimicrobial activity exhibited by Bis-salicylaldehyde ethylenediamine and its Lanthanoid (III) complexes against bacterial and fungal isolates, both will not be potential antibacterial agent but Bis-salicylaldehyde ethylenediamine could be pontential antifungal agent. We therefore, recommend further researches geared toward exploring its full potentials for antifungal therapy.

Published
2022
Full Text
View/download PDF

50. Characterization of Magnetorheological Finishing Fluid for Continuous Flow Finishing Process.

Author

Manga, S. K. and Kataria, M.

Subjects
MAGNETORHEOLOGICAL fluids, FLUID dynamics, TAGUCHI methods
Abstract

Magnetorheological (MR) fluid finishing process is an application of MR technology in which controllability of the MR fluid is used advantageously to finish the workpiece surface. MR finishing fluid changes its stiffness in accordance with the applied magnetic field and hence it behaves like a flexible finishing tool. A relative motion between this tool and workpiece removes the material from the machining surface. The quality of the final finished surface depends on the constituents of the finishing fluid and the applied magnetic field strength as these parameters affect the rheological properties of the fluid. A study on the rheological properties of the fluid at high shear rates is carried out through Taguchi Design of Experiments to characterize its flow behaviour to be used in continuous flow finishing process. Constitutive modeling of the fluid sample is done using Bingham Plastic, Casson Fluid and Herschel Bulkley fluid models to characterize their rheological behavior. The Hershel-Bulkley model is found to be the best suited model for the finishing fluid. Analysis of Variance has revealed that volume percentage of iron particles is the most significant parameter with a contribution of 91.68% on the yield stress and viscosity on the finishing fluid. The highest yield stress of the fluid is observed between magnetic flux density ranges from 0.3 to 0.5 Tesla. An optimised combination is then synthesized to confirm the theoretical results. The effect of temperature is also studied on the optimised fluid which has shown that temperature shares an inverse relation with the yield stress of the finishing fluid. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results